newco hold pattern like benefit closest
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim jan
price data feb
rate updat feb
currenc amount express
methodolog valu compani
despit impress billion new product launch
invest made asthma treatment
wixela oncolog drug fulphila fourth-quart
revenu billion slightli short capit iq
consensu expect normal earn per
share came slightli higher consensu
project due strong cost control manag
provid transit fiscal guidanc stand-alon
includ revenu billion
ebitda billion bracket capiq
consensu project maintain no-moat
rate fair valu estim
unanticip complex involv revers
morri trust transact seem extend
anticip upjohn merger close slight
departur initi indic may close
signific extens propos close timelin could
distract prolong implement
much-need strateg overhaul compet fierc
competit dynam gener market opinion
announc manag chang especi cfo
appoint notabl upjohn
tenur
instrument new team need aggress
pipelin upjohn global
infrastructur brand expertis estim
implement take time benefit probabl
realiz coupl year confirm
manag plan present newco viatri
baselin trough year close somewhat compar
two-year aggress transform unfold
teva signific leverag duress
eagerli await introduct hybrid valu
proposit merg compani concern
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
regist netherland lead gener drugmak
roughli manufactur facil although compani
form compani posit second-largest gener
compani larg attribut acquisit matrix laboratori
gener busi germany-bas merck kgaa portfolio
gener specialti over-the-count activ
ingredi medicin
manufactur epipen treatment anaphylaxi acquir
merk kgaa transact
predominantli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
may dilut
prolong
competit posit without much clariti
hold period prefer teva share think
worth compani alreadi start benefit
aggress restructur
similar three-prong strateg overhaul employ
closest peer anticip viatri need employ
follow aggress step ration matur
unprofit commod product across two platform
implement signific cost-sav initi strive
effici tune multipl billion reinvest
develop new specialti biosimilar drug
significantli price stabil similar
develop recent launch off-set
natur eros gener busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
